Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial
dc.contributor.author | Kristeleit, R. | |
dc.contributor.author | Clamp, Andrew R | |
dc.contributor.author | Gourley, C. | |
dc.contributor.author | Roux, R. | |
dc.contributor.author | Hall, M. | |
dc.contributor.author | Devlin, M. J. | |
dc.contributor.author | Nirsimloo, R. | |
dc.contributor.author | Kounnis, V. | |
dc.contributor.author | Hughes, L. | |
dc.contributor.author | Counsell, N. | |
dc.contributor.author | Farrelly, L. | |
dc.contributor.author | Miller, R. | |
dc.date.accessioned | 2023-01-24T10:32:22Z | |
dc.date.available | 2023-01-24T10:32:22Z | |
dc.date.issued | 2022 | en |
dc.identifier.citation | Kristeleit R, Clamp AR, Gourley C, Roux R, Hall M, Devlin MJ, et al. Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial. Annals of Oncology. 2022 Sep;33(7):S783-S. PubMed PMID: WOS:000866211600514. | en |
dc.identifier.doi | 10.1016/annonc/annonc1054 | en |
dc.identifier.uri | http://hdl.handle.net/10541/625959 | |
dc.language.iso | en | en |
dc.relation.url | https://dx.doi.org/10.1016/annonc/annonc1054 | en |
dc.title | Efficacy of pembrolizumab monotherapy (PM) for advanced clear cell gynaecological cancer (CCGC): Phase II PEACOCC trial | en |
dc.type | Meetings and Proceedings | en |
dc.contributor.department | Department Of Oncology, Guy's and St Thomas' NHS Foundation Trust, SE1 9RT | en |
dc.identifier.journal | Annals of Oncology | en |
dc.description.note | en] |